T
TCRT icon

Tidemark’s Alaunos Therapeutics TCRT Stock Holding History

Tidemark’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5 Hold
2
– – ﹤0.01% 935
2026
Q1 		$6 Hold
2
– – ﹤0.01% 900
2025
Q4 		$6 Buy
+2
New +$6 ﹤0.01% 658
2025
Q2 		– Sell
-2
Closed -$3 – 752
2025
Q1 		$3 Buy
+2
New +$3 ﹤0.01% 703
2024
Q4 		– Sell
-2
Closed -$6 – 679
2024
Q3 		$6 Sell
2
-1
-33% -$4 ﹤0.01% 623
2024
Q2 		$18 Hold
3
– – ﹤0.01% 619
2024
Q1 		$47 Hold
3
– – ﹤0.01% 690
2023
Q4 		$28 Buy
+3
New +$36 ﹤0.01% 689

Other funds holding TCRT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Tower Research Capital (TRC)
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Arax Advisory Partners
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Tidemark's TCRT Position: Q2 2026 in Review

Tidemark held its Alaunos Therapeutics (TCRT) position steady in Q2 2026 at 2 shares worth $5. The position accounts for ﹤0.01% of the portfolio, ranked #935.

Tidemark first reported a position in TCRT in Q4 2023 and has held it in 8 quarters since. The position peaked at $47 in Q1 2024. 29 funds tracked by Wall St. Rank hold TCRT as of Q2 2026.

  • Tidemark held 2 shares of Alaunos Therapeutics worth $5 as of Q2 2026.
  • Tidemark left its Alaunos Therapeutics share count unchanged in Q2 2026.
  • Alaunos Therapeutics made up ﹤0.01% of Tidemark's portfolio in Q2 2026, its #935 holding.
  • Tidemark first reported a position in Alaunos Therapeutics in Q4 2023 and has held it in 8 quarters since.
  • Tidemark's Alaunos Therapeutics position peaked at $47 in Q1 2024.
  • 29 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2026.

Based on Tidemark's 13F filing for Q2 2026, filed 10 Aug 2026.